TLDR;
This video provides a comprehensive overview of tuberculosis (TB), covering its etiology, risk factors, pathophysiology, clinical findings, diagnostic approaches, and treatment strategies. It emphasizes the importance of understanding the pathogen Mycobacterium tuberculosis, its unique characteristics, and the host's immune response in determining the course of the disease.
- Mycobacterium tuberculosis has micolic acids, long doubling time, and virulence factors.
- TB spreads via respiratory droplets, with risk factors including endemic exposure, close contact, and immunosuppression.
- TB can manifest as latent, primary progressive, or reactivation TB, each with distinct characteristics and diagnostic findings.
Etiology of Tuberculosis (TB) [0:25]
The primary pathogen responsible for tuberculosis is Mycobacterium tuberculosis. This bacterium has a unique cell wall structure, including a cell membrane, peptidoglycan layer, arabinogalactan layer, and most importantly, micolic acids. The micolic acids resist decolorization during acid-fast staining, causing the bacteria to remain red under the microscope, a key characteristic for identification. Mycobacterium tuberculosis has a very long doubling time, leading to slow growth, which can take up to six weeks for cultures to grow, making diagnosis challenging. It is an obligate aerobe, preferring areas with high oxygen tension, such as the apex of the lungs.
Risk Factors for TB [12:49]
Exposure to Mycobacterium tuberculosis occurs primarily through respiratory droplets, typically in close proximity to an individual with active TB. Risk factors for exposure include endemic exposure, such as being born in or traveling to areas with high TB prevalence like Asia, Africa, and Latin America. Close contact exposure, especially with someone who has active TB, significantly increases the risk. High-risk areas such as hospitals, homeless shelters, and prisons also elevate the risk of exposure.
Pathophysiology of TB [27:01]
Following exposure, the body responds in one of two ways: either the infection progresses, or it becomes dormant. In most cases (over 90%), the immune system walls off the bacteria, leading to latent TB. In less than 10% of cases, particularly in individuals with weakened immune systems, the infection progresses, leading to primary progressive TB. Reactivation TB occurs when a previously dormant infection reactivates, often in the upper lobes of the lungs due to high oxygen tension, leading to liquefactive necrosis.
The immune response involves T-helper (TH) cells, specifically CD4 cells, which secrete interferon-gamma to activate macrophages. Macrophages release TNF-alpha, further activating T-cells and recruiting more macrophages. This process aims to encapsulate the bacteria within a granuloma. Conditions that suppress the immune system, such as HIV/AIDS or the use of immunosuppressants like TNF-alpha inhibitors, can disrupt this process, leading to active TB.
Latent vs. Active TB [57:52]
Latent TB is characterized by dormant bacteria contained within granulomas, with no active replication or tissue destruction. Active TB, whether primary progressive or reactivation, involves active bacteria causing damage to lung tissue. Primary progressive TB often presents as middle or lower lobe consolidation, while reactivation TB typically involves cavitary lesions in the upper lobes. Active TB can also spread beyond the lungs, leading to extrapulmonary TB.
Clinical Findings and Complications of TB [1:14:43]
Pulmonary TB often presents with fever, night sweats, weight loss, and a productive cough, potentially with hemoptysis. Reactivation TB is more likely to cause a productive cough than primary progressive TB. Complications include TB pleural effusion, miliary TB (characterized by diffuse nodular lesions throughout the lungs), TB meningitis (inflammation of the meninges at the base of the brain), POTS disease (TB osteomyelitis affecting the vertebrae), TB lymphadenitis (scrofula, involving cervical lymph nodes), TB pericarditis (inflammation of the pericardium), TB peritonitis (inflammation of the peritoneum), adrenal TB (leading to Addison's disease), and genitourinary TB.
Diagnostic Approach to TB [1:32:20]
The diagnostic approach begins with assessing risk factors for TB exposure and active infection. If TB is suspected, the next step is to determine if the patient has memory T-cells, which indicates prior exposure. This is done using an interferon-gamma release assay (IGRA) or a tuberculin skin test (TST). The choice between these tests depends on whether the patient has received the BCG vaccine. A chest X-ray is then performed to look for signs of lung tissue destruction.
If the chest X-ray is abnormal, further testing is needed to confirm active TB. This involves obtaining sputum samples for acid-fast bacillus (AFB) smear, nucleic acid amplification test (NAAT), and mycobacterial culture. If extrapulmonary TB is suspected, organ-specific workups are performed, including imaging and fluid or tissue biopsies.
Treatment of TB [2:09:24]
Treatment for latent TB typically involves rifampin for four months or isoniazid for six to nine months. Active TB requires a more aggressive approach, using a combination of drugs known as the RIPE regimen: rifampin, isoniazid, pyrazinamide, and ethambutol, all four drugs for two months, followed by rifampin and isoniazid for an additional four months. Patients on these medications must be monitored for side effects, including hepatotoxicity, peripheral neuropathy, hyperuricemia, and optic neuritis. Treatment duration may be extended in cases of TB meningitis, POTS disease, or persistent positive sputum cultures.
